BCIQ Profiles

Company Profile Report
0518 Agenus TIGIT EMB Tue 0730 ET
BioCentury & Getty Images


BMS sees potential first-in-class therapy in deal for Agenus’ bispecific TIGIT-targeting mAb

May 18, 2021 | 11:36 AM GMT

BMS’s belief that Agenus has built a differentiated TIGIT-targeting bispecific molecule has resulted in a potentially transformative deal for the biotech, delivering $200 million up front for the preclinical program to fuel its further

Read the full 628 word article

How to gain access

Continue reading with a
two-week free trial.